Idiopathic infratentorial superficial siderosis of the central nervous system: case report and review of literature by Stabile, Andrea et al.
Case Report and Review
Idiopathic infratentorial superficial siderosis of the
central nervous system: case report and review of
literature
Andrea Stabile a, Vincenzo Di Lazzaro b, Cesare Colosimo c, Fabrizio Piazza d,
Carlo Ferrarese a,d, Jacopo C. DiFrancesco a,d,*
aDepartment of Neurology, ASST San Gerardo Hospital, Monza, Italy
bUnit of Neurology, Neurophysiology, Neurobiology, Department of Medicine, University Campus Bio-Medico, Rome,
Italy
cRadiology and Neuroradiology Unit, Diagnostic Imaging Area, Fondazione Policlinico Universitario A. Gemelli,
Institute of Radiology, School of Medicine, Catholic University, Rome, Italy
dMilan Center for Neuroscience, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 1 0 2 – 1 0 6
a r t i c l e i n f o
Article history:
Received 11 September 2017
Accepted 18 October 2017
Available online 27 October 2017
Keywords:
Superﬁcial siderosis
Cerebral amyloid angiopathy
Hemosiderin
Brain Magnetic Resonance Imaging
(MRI)
Susceptibility weighted imaging
a b s t r a c t
The superﬁcial siderosis (SS) of the central nervous system (CNS) is a rare condition
characterized by a wide range of neurological manifestations directly linked to an acquired
iron-mediated neurodegeneration. First described more than 100 years ago, only recently SS
has been divided into two distinct entities, according to the distribution of iron deposition in
the CNS: cortical superﬁcial siderosis (cSS) and infratentorial superﬁcial siderosis (iSS). Here
we describe an adult case of iSS, with detailed clinical and radiological features. Moreover,
we extensively review the literature of SS, particularly focusing on the pathogenesis,
clinical-radiological classiﬁcation, diagnostic algorithm and treatment options of this rare
condition.
© 2017 Published by Elsevier Sp. z o.o. on behalf of Polish Neurological Society.
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A 45-year-old Caucasian man presented with an 8-year history
of slowly progressive gait difﬁculties, tinnitus and emotional
liability. The patient also reported pharmacoresistant migraine* Corresponding author at: Department of Neurology, San Gerardo Hosp
Via Pergolesi, 33, 20052 Monza (MB), Italy.
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number of attacks over the last few years. At the age of 27, he
experienced a transient episode of acute headache and diplopia
without papilledema, treated with oral corticosteroid therapy
with gradual resolution of the symptoms. At that time, brain
computed tomography (CT) scan, brain and spinal cord
magnetic resonance imaging (MRI) were unremarkable.ital, School of Medicine and Surgery, University of Milano-Bicocca,
o@gmail.com (J.C. DiFrancesco).
eurological Society.
Fig. 1 – Brain MRI showing the principal neuroradiological features of iSS. (A) Coronal FSE T2-weighted image. (B) Axial
fat-saturated FSE T2-weighted image. (C) Axial SWI T2*-weighted image. On FSE T2-WI (A and B) only a faint rim of
hypointensity is seen on the brainstem and cerebellar surface. On T2*WI obtained by susceptibility weighted imaging
sequence (SWI) there is a prominent evidence of paramagnetic deposition (hemosiderin) along the surface of the brainstem
and cerebellum, as well as on the cisternal course of cranial nerves.
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echo (GRE) and susceptibility-weighted imaging (SWI)
sequences, revealed a prominent hypointensity mainly along
the surface of the infratentorial structures, particularly on the
surface of the brainstem, the intracranial part of facial and
vestibulocochlear nerves bilaterally and the cerebellum
(paravermis cerebellar cortex and dentate nuclei), associated
with atrophy of the cerebellar vermis (Fig. 1). No intrapar-
enchymal hemorrhagic lesions, nor contrast enhancement
were reported. No signs of intracranial hypertension nor
pseudotumor cerebri were identiﬁed. Spinal cord MRI did not
reveal any relevant disease, such as neoplasms, vascular
malformations and dural abnormalities, in particular dural
ﬁstula or intraspinal ﬂuid-ﬁlled collection.
The patient was then admitted to our Department for
further diagnostic investigations. There was no evidence of
arterial hypertension nor injury of the brain and spinal cord.
Familiar history was unremarkable for neurological diseases.
Neurological examination revealed horizontal bilateral nys-
tagmus, minor increase in muscle tone at the lower limb
bilaterally and hypoesthesia/dysesthesia at the left lower limb.
Deep tendon reﬂexes were diffusely brisk and Babinski's sign
was slightly positive bilaterally. Slight oscillations in Romberg
were noted and gait was wide-based and unsteady, without
marked ataxic features. The patient did not report neck
stiffness or hearing loss. There was no abnormality in his
coordination and no evidence of cognitive impairment.
Routine laboratory tests were unremarkable. Cerebral and
cervical digital subtraction angiography (DSA) resulted nega-
tive for aneurysms, other vascular malformations or any cause
of hemosiderin deposition. The patients refused the execution
of the lumbar puncture. The electromyography excluded the
presence of polyneuropathy. Rectal mucosa biopsy excluded
systemic amyloidosis.
Based on clinical features and neuroimaging ﬁndings, no
major cause of occult bleeding in the CNS was identiﬁed and
diagnosis of idiopathic iSS of the CNS was performed.2. Review of literature
The SS of the CNS is an acquired neurological disorder
resulting from hemosiderin deposition in the subpial layers
of the brain, cranial nerves and spinal cord producing a
progressive white matter and neuronal damage [1]. Hamill
deﬁned SS as ‘‘melanosis of the brain, cord and meninges’’ in
the ﬁrst report in literature [2]. Although previously deﬁned as
a rare condition, thanks to the development of speciﬁc MRI
sequences for the detection of hemosiderin in the CNS, SS has
been increasingly recognized in the recent past.
Even if the pathogenic mechanisms are not known yet, SS is
supposed to result from a subtle, low-volume, enduring or
repetitive, leakage of blood (‘‘minor bleeding’’) into the
subarachnoid space [3]. Other important phases contribute
to the clinico-radiological expression of SS: blood dissemina-
tion by the cerebrospinal ﬂuid (CSF), hemolysis and entrance of
heme into the exposed tissue, conversion of heme in free iron,
ferritin and hemosiderin and, in the end, direct tissue damage.
Only CNS tissues convert the heme in CSF to hemosiderin. In
response to the exposure to the heme, Bergmann glia and
microglia synthetize hemoxygenase-1 (HO-1) and ferritin. HO-
1 breaks down the heme into free iron and biliverdin, while
ferritin binds free iron to produce hemosiderin, the primary
cause of the ‘‘dark rim’’, corresponding to the radiological
hallmark of SS [4,5]. Chronic or intermittent red blood cells'
extravasation in the subarachnoid space overwhelms toxic
iron sequestering of glial cells, leading to iron accumulation
with oxidative damage, membrane dysfunction and conse-
quent neurodegeneration [1]. Usually, a period of many years
is between the bleeding and the onset of the clinico-
radiological signs of SS [5]. In the CNS, the posterior fossa
seems to be mainly affected by the iron deposition because of
the abundance of microglia and Bergmann glia, in particular in
the cerebellum and vestibulocochlear nerves [6]. Furthermore,
secondary atrophy of the cerebellar convexities and superior
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relation to the pattern of CSF ﬂow [7]. In this scenario, basal
frontal lobes, mesial temporal lobes, optic nerves, olfactory
tracts, spinal cord and ﬁlum terminalis are also particularly
vulnerable to the toxic insult of hemosiderin deposition [8].
According to the different radiological features, clinical
presentation and etiology, two principal patterns of SS are
recognizable: cortical superﬁcial siderosis (cSS) and infraten-
torial superﬁcial siderosis (iSS) [5]. cSS is restricted to the
supratentorial structures of the CNS, in particular, the
convexities of the cerebral hemispheres [9,10]. Probably, cSS
follows from residues originated by subacute and chronic
bleeding, mainly from subarachnoid hemorrhage (SAH) [8,10].
This differentiates cSS from acute convexity SAH, which rather
shows blood products in hyperacute or acute stages [4]. Based
on the extent, cSS is classiﬁed as focal, if three or fewer sulci
are affected, or disseminated, if at least four sulci are involved.
Among the possible etiologies of cSS, prior or recent head
trauma should be excluded ﬁrst; then a non-traumatic etiology
should be investigated [4]. Cerebral amyloid angiopathy (CAA),
a cerebral small vessel disorder typical of the old age [11], was
identiﬁed as the most frequent non-traumatic cause of cSS
[12]. CAA is characterized by progressive amyloid-b accumu-
lation within cortical and leptomeningeal vessel walls [13],
causing both hemorrhagic and ischemic brain injury [13,14]. It
is associated with spontaneous symptomatic lobar intracere-
bral hemorrhage (ICH) (>5 mm in diameter) [13], and other
distinctive MRI red ﬂags represented by multiple lobar
microbleeds (<5 mm in diameter) [15], white matter hyper-
intensity (leukoaraiosis), cSS [10] and cerebral microinfarcts
[14]. There are several mechanisms by which CAA can cause
cSS: the ﬁrst is due to repeated episodes of acute SAH from
fragile leptomeningeal or superﬁcial cortical CAA-affected
vessels; a second mechanism relates to the leakage or
expansion of a lobar ICH or superﬁcial lobar microbleeds into
the subarachnoid space; the last one consists in hemorrhagic
transformation of small cortical infarcts [4]. Linn et al.
established the primary subarachnoid bleeding as the most
likely mechanism underling the pathogenesis of cSS [10].
Other conditions associated with cSS include: reversible
cerebral vasoconstriction syndrome (RCVS), primary angiitis
of the CNS (PACNS) [16], CAA-related inﬂammation (CAA-ri)
[17–20], hyperperfusion syndrome after revascularization
(carotid stenting or carotid endoarterectomy), cortical vein
occlusions, posterior reversible leukoencephalopathy syn-
drome (PRES), parent vessel stenosis, coagulopathy, drug
use, cavernoma and brain abscesses [21]. Clinically cSS can
present with headache, focal neurological deﬁcits, transient
focal neurological episodes (also known as ‘‘amyloid spells’’
[22], which can mimic transient ischemic attacks), and
cognitive impairment [23], in particular when a disseminated
form of siderosis is detected [12].
iSS is a recently recognized clinico-radiological entity,
deﬁned by the siderosis involving bilaterally the surface of at
least two of the regions: brainstem (including midbrain, pons,
medulla), cerebellum (including cerebellar folia, cerebellar
peduncles, vermis), spinal cord or craniocervical junction, with
or without supratentorial spreading [5]. Typically, iSS is
present in the crests of cerebellar folia, superior vermis,
vestibulocochlear nerves, quadrigeminal plate and basalcerebral surface, but it may also engage interhemispheric
ﬁssure, Sylvian ﬁssure, cortical sulci and the pial surface of the
cord. There is a wide range of hypothesized pathogenetic
causes of iSS, including SAH from intracranial aneurysms,
arteriovenous malformations, tumors, CAA and spinal epidu-
ral CSF collections [24,25]. On the basis of the presumed
etiology, Wilson et al. also identiﬁed two distinct groups of iSS
termed ‘‘classical’’ or type 1 iSS and ‘‘secondary’’ or type 2 iSS.
Classical/type 1 iSS occurs when there is no obvious,
spontaneous or traumatic, CNS bleeding that could account
for siderosis. It is mainly linked to dural abnormalities (mainly
pseudomeningocele, extra-arachnoid CSF collection, dural
ectasia), but CNS tumors, previous spinal trauma or previous
neurosurgery, nerve root avulsion, brachial plexus injury and
rarer diseases inducing injury or distortion of the dura (such as
neuroﬁbromatosis 1, Marfan syndrome, ankylosing spondy-
losis) have also been reported. In this case, the bleeding source
has low pressure, probably originating from microvascular or
venous blood leakage and most likely arising in the spine or in
the posterior fossa at the site of a dural defect [5,26]. Indeed,
type 1 iSS is clinically characterized by the slowly progressive
onset of at least one symptom of the typical triad: sensori-
neural hypoacusia, cerebellar ataxia, myelopathy (with pyra-
midal signs). Other frequent neurological manifestations are
bladder/bowel defects (mainly sphincter dysfunction), swal-
lowing deﬁcits and anosmia [5]. Other neurological manifesta-
tions mentioned in cases already reported in literature before
the classiﬁcation proposed by Wilson et al. and ascribable to
the classical form of iSS, are represented by seizures, memory
impairment leading to dementia [27], anisocoria and sensory
signs. Less frequent features include ageusia, headache, back
pain [24], cranial nerve palsies and lower motoneuron signs.
Secondary or type 2 iSS occurs when there is an evident single
hemorrhage (spontaneous ICH, aneurysmal SAH, intraventric-
ular hemorrhage, surgical trauma and bilateral subdural
hemorrhages) that, based on its spatial distribution and
timing, is thought to be the cause of siderosis. In this case,
a signiﬁcant volume of blood rapidly accumulates (high-
pressure arterial leak) and is deposited in the subpial layers of
the CNS tissue, mainly around the site of bleeding [5].
Therefore, clinical correlates are characterized by an acute
onset [5], the location of hemosiderin deposition corresponds
to the symptomatic areas of the CNS and its amount is
proportional to the disease burden.
Before the advent of MRI, SS of the CNS could only be
diagnosed by clinical ﬁndings and CSF analysis, with a
conﬁrmation possible only post-mortem by histopathological
examination of the brain and spine [28]. With the increasing
use of neuroimaging and the development of the iron-
sensitive sequences, MRI of the brain and spinal cord has
become the cornerstone for the diagnosis of SS. MRI
appearance of SS results from paramagnetic blood by-
products (hemosiderin), which cause local magnetic ﬁeld
inhomogeneity producing a signal loss on T2*-GRE and SWI
sequences with a characteristic linear/gyral pattern beneath
all CNS surfaces in contact with the CSF; in particular the
availability of SWI resulted in a superior sensitivity in
detecting siderosis and other paramagnetic effects [29].
Ependymal hypointensity may also occur in severe forms
of siderosis. This could be related to the reﬂux of hemorrhagic
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outside the ventricular system. Other investigations aimed to
locate a possible bleeding source in the CNS include
computed tomographic angiography, magnetic resonance
angiography, intra-arterial DSA of the brain or the spine, CT
myelography [8] and surgical exploration. As reported in the
ﬂow-chart for iSS diagnostic process, CSF analysis still
preserves a role, mainly for red blood cells count, ferritin,
oxyhemoglobin and bilirubin evaluation [5]. CSF is usually
altered in up to 75% of cases of SS with abundant red cells and/
or xanthochromia, elevated protein and ferritin levels.
According to this diagnostic pathway, in Wilson's population
a cause of the SS was found in the 94% of patients with
classical iSS, while only 6% remained without an underlying
etiology [5]. This rate of diagnostic accuracy is signiﬁcantly
higher compared to the 35% of unexplained cases of SS
reported previously in literature and termed ‘‘idiopathic’’ [1].
The natural history and clinical evolution of SS are poorly
understood. The identiﬁcation and resolution of the bleeding
source do not bring to a prompt clinical recovery or radiological
reversal of SS in the majority of cases [30]. Several therapeutic
approaches have been proposed, however with a mild beneﬁt.
These can be divided into two groups: the ﬁrst, aimed at
ablating the source of bleeding (essentially surgical
approaches) and the second, aimed at reverting iron deposi-
tion (principally pharmacological approaches). Surgical treat-
ment of SS has the goal of interrupting the blood leakage into
subarachnoid space and consists in repairing the structural
CNS abnormality, such as nerve root avulsion, arteriovenous
malformation, dural defect, meningocele, vessels and possible
membranes associated with pseudomeningocele [5,27]. How-
ever, despite some cases report a clinical improvement after
surgical procedures, most of the authors agree that the disease
progresses secondarily, even without an evident source of
bleeding, with an unknown mechanism, likely related to the
established overload of iron in the CNS [27]. The pharmaco-
logical treatment of SS includes different strategies, mainly
aimed at iron chelation. During the past years, different
medications have been experimented: desferrioxamine [1];
trientine and, eventually, deferiprone [31–33]. Koeppen and
Dickson reported a dramatic reduction in CNS hemosiderin
deposition in an animal model of SS using tin-protoporphyrin
[34], an inhibitor of HO-1, but no randomized trial was
conducted in humans. Although the absence of disease-
modifying treatments in classical iSS, there is a preliminary
evidence for the safety and tolerability of deferiprone
[31,32,35], which is the only iron chelator crossing the
blood–brain barrier and binding hemosiderin in the CNS
[36]. Deferiprone was approved for the treatment of thalasse-
mia with iron overload secondary to blood transfusion in the
USA in October 2011 [33]. Levy et al. reported the ﬁrst case of SS
treated with deferiprone in literature, showing MRI reduction
in hemosiderin deposition in the brain [31]. A subsequent
small trial on 10 participants with SS conﬁrmed the positive
trend on the MRI of four patients treated for 90 days [32].
However, no clinical improvement was observed and further
studies are needed to better evaluate the efﬁcacy of defer-
iprone [32]. Another possible pharmacological approach is
represented by corticosteroids. These were used with clinical
beneﬁt in a single case of SS associated with anti-Riautoimmune disease [37], while resulted ineffective in others
[38,39].
3. Discussion
SS is a neurological entity still barely diagnosed, without a
speciﬁc treatment available. Brain MRI with iron-sensitive
sequences represents the ﬁrst-line approach to recognize and
characterize SS of the CNS. Standardized radiological techni-
ques are important to classify the different patterns of
presentation of SS. Wilson et al. proposed novel diagnostic
criteria, which are inspirational for future clinical research,
with the ﬁnal aim to identify a potential treatment. Neverthe-
less, besides accurate MRI studies, in the diagnostic ﬂow-chart,
it is important to keep in mind all the investigations useful for
the identiﬁcation of the site of bleeding.
The patient here reported showed neurological signs highly
suggestive of classical iSS, mainly a mild spasticity at lower
limbs with imbalance and gait abnormality, associated with the
radiological evidence of hemosiderin deposition in the posteri-
or fossa. Nonetheless, he also presented with other less
canonical manifestations, such as migraine, tinnitus and
lateralized hypoesthesia/dysesthesia at the lower limbs, which
conditioned his long diagnostic history. Notably, although we
were not able to perform a lumbar puncture, his radiological
picture is indicative of a form of idiopathic iSS, as supported by
brain and spinal cord MRI and cerebral and cervical DSA, all
resulted negative for any possible cause of bleeding.
Since the neurological damage is related to the time of
exposure to iron toxic effect, a rapid diagnosis of SS and a
prompt comprehension of its etiological mechanism would be
desirable in order to treat the underlying condition, mostly
with a surgical approach. In those cases remained without a
documented bleeding source after appropriate diagnostic
investigations, the development of new pharmacological
treatments would be crucial to facilitate the disposal of the
dangerous iron load and to provide the damaged nervous
structures with the substrate necessary to promote a func-
tional improvement.
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